Mountain View,  CA 
United States
  • Booth: 1007

Cellecta is a trusted provider of genomic products and services.

Our functional genomics portfolio includes gene editing capabilities such as:

  • gene loss-of-function and gain-of-function screens resulting from gene knockout, activation or knockdown
  • custom and genome-wide CRISPR, CRISPRa, CRISPRi and RNAi libraries
  • construct services 
  • cell line engineering services 
  • next-generation sequencing (NGS) kits for CRISPR and shRNA libraries.

For targeted gene expression profiling in applications such as biomarker or drug target discovery or tumor microenvironment analysis, Cellecta offers the DriverMapTM Human Genome-Wide Gene Expression Profiling Assay as a service or as a kit. The DriverMap assay, an easy to use, single-tube, multiplex reaction, is up to 100x more sensitive than RNA-Seq or microarray methods.

We also offer CellTrackerTM individual barcodes and barcode libraries.

Visit Booth 1007 or www.cellecta.com

Brands: DriverMap CellTracker

 Press Releases

  • Libraries of pooled lentiviral constructs that express two different sgRNA to all 19,000 human protein-coding genes improve overall gene activation or repression and generate more robust screening results

    MOUNTAIN VIEW—(PR Newswire)—June 26, 2019—Cellecta, Inc. today announced the launch of the first commercially available dual-sgRNA libraries designed for CRISPR activation (CRISPRa) and CRISPR interference/repression (CRISPRi) genetic screens. These new pooled libraries enhance activation or repression of genes to produce more robust results from genetic screens.

    With the modified CRISPRa and CRISPRi systems, the standard CRISPR gene knockout capacity has been re-engineered to modulate gene activity. These variations of the standard CRISPR system extend the types of genetic screening possible. For example, CRISPRa can be used to screen for genes that change phenotypes when activated, rather than disrupted. These “gain-of-function” screens are not possible with the standard CRISPR knockout system.

    Natural gene expression regulation factors often bind at multiple sites on a promoter to produce a synergistic activation or repression effect. Similarly, Cellecta’s novel dual-sgRNA CRISPRa and CRISPRi libraries enhance the activity of the standard single-sgRNA libraries because each construct expresses two different sgRNA binding distinct sites on the promoter of each gene target. This increases the likelihood that each targeted gene will be activated or repressed above a given threshold when compared to libraries where only a single sgRNA targets a gene promoter.

    Donato Tedesco, director of R&D at Cellecta, notes, “We found several examples where targeting more than one sgRNA to the same promoter enhanced expression levels of the target gene using the CRISPRa system, even when one sgRNA by itself had no detectable effect. As a result, it made sense to build a library where each construct has more than one sgRNA targeting each gene. We expected this to increase the overall level of effectiveness for the library and indeed, this is what we saw when we compared the overall expression levels of our single-sgRNA CRISPRa library with the dual-sgRNA version.”

    Over the past few years, many research laboratories have taken advantage of single-sgRNA libraries to perform CRISPRa, CRISPRi and standard CRISPR knockout screens to identify potential therapeutic targets responsible for controlling growth and differentiation, regulating disease development, or other biological responses. The development of the new dual-sgRNA CRISPRa and CRISPRi libraries extends the range of tools available for functional genetic screening and accelerates the identification of novel targets for therapeutics and biomarker analysis. 

    For more information, please visit ASHG booth 1007.

  • Five RNA-Seq assay panels target known gene sets associated with human disease, drug response, immune responses, related phenotypes

    MOUNTAIN VIEW—(PR Newswire)—December 10, 2018—Cellecta, Inc. today announced the launch of five DriverMap™ Predesigned RNA-Seq Panels. Each panel measures expression levels of over 1200 expertly curated essential genes selected from publications, open access databases, and other resources.

    DriverMap™ Predesigned Panels use the same multiplex RT-PCR followed by Next-Generation Sequencing (NGS) approach as the genome-wide DriverMap Expression Profiling assay that measures expression levels of all protein-coding human genes. DriverMap kits also come with genome alignment software that delivers differential expression data in an Excel spreadsheet format.

    “The comprehensive, expertly curated DriverMap panels target complex sets of genes that enable a thorough and simple analysis of key responses in a range of human models,” said Alex Chenchik, Ph.D., chief scientific officer and president of Cellecta. “Combining manual curation with data from the most important public databases such as ENCODE, FANTOM, ImmGen, the Human Primary Cells Atlas (HPCA), DrugBank, LINCS, MSigDB, and others, we were able to create panels that provide pertinent data to identify and analyze biologically interesting expression signatures and putative markers in therapeutic and diagnostic models.”

    Five DriverMap™ Predesigned RNA-Seq Panels are available:

    • DriverMap Human Cell Marker Panel – enables gene signature-based analysis and quantitative evaluation of 64 unique immune and stromal cell types by measuring the expression levels of 1,285 human protein-coding genes.

    • DriverMap Human Hallmark Signatures Panel – encompasses 50 unique hallmarks obtained from analysis of the Molecular Signatures Database (MSigDB) by measuring the gene expression of 4,304 human genes.

    • DriverMap Human LINCSx Panel – contains gene signatures of “landmark genes” from the LINCS and DrugBank databases, which catalog gene expression changes that result from exposure to perturbing agents and to drugs approved by the US Food and Drug Administration in the past 30 years. The expression levels of 1,573 genes are measured.

    • DriverMap Human Pan-Cancer Pathway Panel – contains novel gene signatures of molecular pathways often dysregulated in cancer as reported in the scientific literature. The expression levels of 2,094 protein-coding genes are measured.

    • DriverMap Human Transcription Factor Signature Panel – enables gene signaturebased inference and quantitative evaluation of 343 key transcription factors by measuring the expression levels of 2,649 genes identified from open-access databases and manual curation.

    The DriverMap™ Predesigned Panel kits include a complete set of gene-specific and PCR-NGS primers, buffers, spike-in ERCC and positive control RNAs, as well as all other reagents required to profile 96 samples and prepare them for digital expression profiling using NGS on an Illumina sequencing platform. NGS reagents are not included in the DriverMap assay kit.

    To facilitate data analysis, DriverMap Alignment Software is included, which enables demultiplexing and visualization of gene-specific expression data in an Excel spreadsheet format directly from Illumina NGS FASTQ raw reads.

    The DriverMap™ Predesigned RNA-Seq Panels and Software are available now. For more information, visit https://www.cellecta.com/drivermap-predesigned-panels or visit ASHG booth 1007.

  • Label individual cells with uniquely identifiable, expressed barcodes to understand how different experimental conditions affect distinct groups of cells from a common progenitor.

    MOUNTAIN VIEW—(PR Newswire)—October 9, 2018—Cellecta, Inc. today introduced the CloneTracker XP™ Expressed Lentiviral Barcode Library and CloneTracker XP™ Barcoded CRISPR Library product lines. The ability to label and trace individual cells is a powerful experimental tool in many research areas including cell development and evolution, stem cell biology or carcinogenesis. Cellecta’s new expressed barcode libraries, together with nextgeneration sequencing (NGS) technology, enable a new approach for tracking clonal variations in large cell populations.

    The new CloneTracker XP Barcode Libraries differ from Cellecta’s standard CloneTracker Barcode Library in that the unique DNA sequence (i.e., the barcode) is designed to express on an RNA transcript in the cells. As a result, it can be detected by either DNA or RNA sequencing. Researchers can use these ready-to-use expressed barcoding libraries to label several million cells each with a unique barcode, and subsequently perform NGS to sort out sub-populations of progeny cells derived from the original progenitors at any point during their experiment. The approach provides a convenient way to identify cell variations with unique characteristics or biology, and to understand how these groups of variant cells evolve in response to drug treatment, tumor metastasis, or other conditions.

    “We are pleased to offer the research community the first commercial libraries that can label large cell populations with cell-specific barcodes detectable in both genomic DNA and expressed RNA cell fractions,” said Alex Chenchik, Ph.D., president and chief scientific officer of Cellecta. “While our standard CloneTracker barcode library can be used to track the evolution of progeny from each cell in the population, these new libraries with expressed barcodes, used in combination with single-cell RNA sequencing, allow researchers to identify which genes are actually activated or shut down in different groups of cells so that, depending on the experiment, they can identify which genes are important for drug resistance, metastasis, cell differentiation, or other processes.” 

    Additionally, a variation of the new CloneTracker XP barcode labeling product that Cellecta now offers introduces a gene effector, in this case CRISPR sgRNA, into the barcode library. Each effector targets and disrupts a specific gene in each of the cells that pick up a barcode. In combination with cell-specific barcode tracking, this gene disruption (or “knockout”), enables researchers to see how particular genetic disruptions change the characteristics of the cells, while simultaneously also identifying the genetic pathways that are activated to produce them. Cellecta now offers two small, pre-made CloneTracker XP Barcoded CRISPR knockout libraries targeting 27 human and mouse anti-cancer genes, as well as custom library development services for CloneTracker XP Barcoded CRISPR Libraries.

    The CloneTracker XP Expressed Barcode libraries are available with barcodes expressed in the 3′- or 5′-UTR of an RNA transcript, and with fluorescent or chemiluminescent reporters. A list of CloneTracker XP™ Expressed Lentiviral Barcode Library formats, as well as examples of relevant applications are available at www.cellecta.com/clonetracker-xp or visit ASHG Booth 1007.


  • DriverMap Targeted RNA-Seq Assay
    A highly sensitive, easy-to-use, targeted expression profiling alternative to RNA-Seq and microarrays, the DriverMap assay enables you to start with as little as 10 pg total RNA to obtain an ultra-sensitive snapshot of your samples' expression profile....

  • Genome-wide expression analysis that combines the sensitivity of multiplex PCR with the dynamic range and throughput of NGS

    • Start with as little as 10 pg total RNA–single-cell level—with no mRNA enrichment
    • One-tube, one-day protocol from RNA to NGS library for sequencing
    • Multiplex NGS readout using Illumina system—no adaptor ligation step
    • More sensitivity than RNA-Seq with 5-10-fold less sequencing depth
    • Simplified analysis against reference sequences—genomic alignment not needed
    • DirectCell protocol to analyze cells directly in oligo-dT microtiter plates—no RNA purification

    The DriverMap™ Human Genome-Wide Targeted Expression Profiling Assay enables researchers to simultaneously measure the expression level of almost 19,000 human protein-coding genes in a single assay. By combining highly multiplexed RT-PCR amplification with the depth and precision of next-generation sequencing (NGS) quantitation, the DriverMap assay provides convenient, comprehensive, highly sensitive, and quantitative measurement of gene expression from total RNA.

    The DriverMap assay starts with total RNA. The targeted, validated primers used in the DriverMap assay specifically amplify the target transcript amplicon sequences with minimal background from other non-target RNAs. As a result, total RNA can be assayed directly without removal of rRNA or globin components. No mRNA enrichment is needed. Any standard RNA sample for RT-PCR is suitable for DriverMap analysis, including total RNA from cells, frozen tissue, fine needle aspirate (FNA), whole blood, peripheral blood mononuclear cells (PBMCs), and mouse patient-derived xenograft (PDX) isolates.

    In addition, the DriverMap assay specifically amplifies human transcripts in a background of mouse or other non-human RNAs. This feature makes it an excellent choice for analysis of PDX samples or similar mixed samples with RNA from human and other organisms.

    For more information, visit www.cellecta.com/drivermap or stop by booth 1007.

Questions or Need Assistance?

Email exhibits@ashg.org

Technical support: Support

For more tips, visit the FAQ.

Featured Products
View All

Want your product featured here? Click to upgrade your online exhibitor listing.